A mycobacterial growth inhibition assay (MGIA) for bovine TB vaccine development
Human tuberculosis remains a significant cause of mortality and morbidity throughout the world. The global economic impact of bovine TB is considerable. An effective vaccine would be the most cost-effective way to control both epidemics, particularly in emerging economies. TB vaccine research would...
Autors principals: | Pepponi, I, Khatri, B, Tanner, R, Villarreal-Ramos, B, Vordermeier, M, McShane, H |
---|---|
Format: | Journal article |
Publicat: |
Elsevier
2017
|
Ítems similars
-
The cross-species mycobacterial growth inhibition assay (MGIA) project 2010-2014
per: Brennan, M, et al.
Publicat: (2017) -
Assessment of the reproducibility and inter-site transferability of the murine direct splenocyte mycobacterial growth inhibition assay (MGIA)
per: Tanner, R, et al.
Publicat: (2021) -
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells
per: Tanner, R, et al.
Publicat: (2021) -
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells [version 1; peer review: 2 approved]
per: Rachel Tanner, et al.
Publicat: (2021-03-01) -
The in vitro direct mycobacterial growth inhibition assay (MGIA) for the early evaluation of TB vaccine candidates and assessment of protective immunity: a protocol for non-human primate cells [version 2; peer review: 2 approved]
per: Rachel Tanner, et al.
Publicat: (2021-09-01)